NCT04296890

Who might be able to join this trial:

• You are a woman aged 18 or older
• You have been diagnosed with high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
• Your cancer has been confirmed to be "platinum-resistant" — meaning if you had only one round of platinum-based chemotherapy, your cancer responded but then came back between 3 and 6 months after your last dose; or if you had two or three rounds of platinum-based chemotherapy, your cancer came back during or within 6 months after your last dose
• Your cancer has been shown on scans to have grown or spread after your most recent cancer treatment
• You are willing to provide a stored tumor tissue sample, or have a low-risk biopsy procedure done, to check for a specific protein called Folate Receptor alpha (FRα)
• Your tumor tissue tests positive for the FRα protein using a specific approved test
• You have at least one tumor that can be measured on a scan
• You have received between 1 and 3 prior cancer treatments overall, including at least one treatment containing a drug called bevacizumab, and a single-drug treatment is considered appropriate as your next step
• Your general health and ability to carry out daily activities is good (confirmed with a standard medical assessment called ECOG Performance Status 0 or 1)
• You have finished your most recent cancer treatment at least a certain number of weeks before starting this trial (confirm with trial site for exact timing based on your treatment)
• Any side effects from previous treatments have mostly resolved or returned to a mild level (hair loss is an exception)
• If you had major surgery, it was completed at least 4 weeks before starting the trial and you have recovered
• Your blood counts, liver, and kidney are all functioning at adequate levels based on blood tests
• You are willing and able to sign a consent form and follow the trial's requirements
• If you could become pregnant, you agree to use highly effective contraception during the trial and for at least 3 months after your last dose
• If you could become pregnant, you have a negative pregnancy test within 4 days before your first dose

Who may not be able to join:

• You are male
• Your ovarian cancer is of a specific type other than high-grade serous — such as endometrioid, clear cell, mucinous, sarcomatous, mixed, or low-grade/borderline
• Your cancer never responded to platinum-based chemotherapy, or came back within 3 months of finishing your first round of platinum treatment
• You have previously had large-area radiation therapy that affected a significant portion of your bone marrow
• You have nerve damage (tingling, numbness, or pain in hands/feet) that is worse than mild
• You have active or ongoing eye conditions such as uncontrolled glaucoma, certain types of macular degeneration, diabetic eye disease with swelling, a history of corneal transplant, or vision in only one eye, among other serious eye conditions
• You have a serious active infection or other significant illness, including active hepatitis B or C, HIV, active cytomegalovirus infection, or any infection currently requiring intravenous (IV) antibiotics
• You have a history of multiple sclerosis, other nerve-related diseases affecting the protective coating of nerves, or Lambert-Eaton syndrome
• You have significant heart problems, such as a heart attack within the past 6 months, unstable chest pain, uncontrolled heart failure, severely uncontrolled high blood pressure, or uncontrolled irregular heartbeat
• You have had a stroke (either bleeding or blockage type) within the past 6 months
• You have advanced liver scarring (cirrhosis) classified as a certain severity level (confirm with trial site)
• You have a history of non-infectious lung inflammation (such as non-infectious interstitial lung disease or pneumonitis)
• You need to take folic acid supplements (for example, due to folate deficiency)
• You have had a serious allergic reaction to antibody-based medications in the past
• You are currently pregnant or breastfeeding
• You have previously been treated with the study drug (MIRV) or any other treatment that targets the FRα protein
• You have cancer that has spread to the brain or spinal cord that is either untreated or causing symptoms
• You have been diagnosed with another type of cancer within the past 3 years (